Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
Laura Cato, Jonas de Tribolet-Hardy, Irene Lee, et al.
Cancer Cell (2019) Vol. 35, Iss. 3, pp. 401-413.e6
Open Access | Times Cited: 158

Showing 1-25 of 158 citing articles:

Prostate cancer
Shahneen Sandhu, Caroline M. Moore, Edmund Chiong, et al.
The Lancet (2021) Vol. 398, Iss. 10305, pp. 1075-1090
Open Access | Times Cited: 399
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
Mark M. Pomerantz, Xintao Qiu, Yanyun Zhu, et al.
Nature Genetics (2020) Vol. 52, Iss. 8, pp. 790-799
Open Access | Times Cited: 231
Epigenetic modulations and lineage plasticity in advanced prostate cancer
Rongrong Ge, Zifan Wang, Rodolfo Montironi, et al.
Annals of Oncology (2020) Vol. 31, Iss. 4, pp. 470-479
Open Access | Times Cited: 157
Transcriptional mediators of treatment resistance in lethal prostate cancer
Meng Xiao He, Michael S. Cuoco, Jett Crowdis, et al.
Nature Medicine (2021) Vol. 27, Iss. 3, pp. 426-433
Open Access | Times Cited: 148
Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
Steven Kregel, Chao Wang, Xin Han, et al.
Neoplasia (2020) Vol. 22, Iss. 2, pp. 111-119
Open Access | Times Cited: 130
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Ugo Testa, Germana Castelli, Elvira Pelosi
Medicines (2019) Vol. 6, Iss. 3, pp. 82-82
Open Access | Times Cited: 117
Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Yingming Li, Rendong Yang, Christine Henzler, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 8, pp. 1965-1976
Open Access | Times Cited: 74
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
Yundong He, Ting Wei, Zhenqing Ye, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 73
CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers
Aaron Waddell, Haojie Huang, Daiqing Liao
Cancers (2021) Vol. 13, Iss. 12, pp. 2872-2872
Open Access | Times Cited: 73
Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
Marzieh Ehsani, Faith Oluwakemi David, Aria Baniahmad
Cancers (2021) Vol. 13, Iss. 7, pp. 1534-1534
Open Access | Times Cited: 61
The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
Zeyuan Zheng, Jinxin Li, Yankuo Liu, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4877-4877
Open Access | Times Cited: 39
Cancer stem cell in prostate cancer progression, metastasis and therapy resistance
Poornima Verma, Neha Shukla, Shivani Kumari, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188887-188887
Closed Access | Times Cited: 36
Rational optimization of a transcription factor activation domain inhibitor
Shaon Basu, Paula Martínez-Cristóbal, Marta Frigolé‐Vivas, et al.
Nature Structural & Molecular Biology (2023) Vol. 30, Iss. 12, pp. 1958-1969
Open Access | Times Cited: 29
Recent advances and future perspectives in the therapeutics of prostate cancer
Ganji Lakshmi Varaprasad, Vivek Gupta, K. Satya Prasad, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 27
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment
Fabio Raith, Daniel H. O’Donovan, Clara Lemos, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2289-2289
Open Access | Times Cited: 25
Mapping cancer biology in space: applications and perspectives on spatial omics for oncology
Sumin Lee, Gyeongjun Kim, JinYoung Lee, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution
Irene Casanova‐Salas, Daniel Aguilar, Sarai Córdoba-Terreros, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1301-1312.e7
Open Access | Times Cited: 13
Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs
Dong Han, Maryam Labaf, Yawei Zhao, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 11
Open Access | Times Cited: 12
Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
Tryambak Srivastava, Ruby Dhar, Subhradip Karmakar
Reproductive Biology and Endocrinology (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
RBPMS inhibits bladder cancer metastasis by downregulating MYC pathway through alternative splicing of ANKRD10
Jingtian Yu, Liang Chen, Gang Wang, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
Suriyan Ponnusamy, Yali He, Dong‐Jin Hwang, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 22, pp. 6764-6780
Open Access | Times Cited: 63
Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors
André Richters, Shelby K. Doyle, David B. Freeman, et al.
Cell chemical biology (2020) Vol. 28, Iss. 2, pp. 134-147.e14
Open Access | Times Cited: 63
Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer
Alexander Kretschmer, Fan Zhang, Syam Prakash Somasekharan, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 62
Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy
Yuning Liao, Yuan Liu, Xiaohong Xia, et al.
Theranostics (2020) Vol. 10, Iss. 8, pp. 3366-3381
Open Access | Times Cited: 60
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts
Hung‐Ming Lam, Holly M. Nguyen, Mark P. Labrecque, et al.
European Urology (2019) Vol. 77, Iss. 2, pp. 144-155
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top